Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party. - Wikidata - awgldk - TriplyDB

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.

http://www.wikidata.org/entity/Q33395411

about

Rituximab for eradicating inhibitors in people with acquired haemophilia A The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality?Autologous haematopoietic stem cell transplantation for systemic lupus erythematosus: data from the European Group for Blood and Marrow Transplantation registry.Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: a 8 case report and literature review.Autologous hematopoietic stem cell transplantation in multiple sclerosis: 20 years of experience.Treatment of refractory ITP and Evans syndrome by haematopoietic cell transplantation: is it indicated, and for whom?Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell Transplant compared with matched sibling and unrelated donor Brief report: Autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the Teff cell compartment Hematopoietic stem cell therapy for multiple sclerosis: top 10 lessons learned.Haematopoietic stem cell transplantation for autoimmune diseases.Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation More immune dysregulation: Sarcoidosis and chronic graft-versus-host disease after allogeneic stem cell transplant.Graft versus self (GvS) against T-cell autoantigens is a mechanism of graft-host interaction High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases.Hematopoietic stem cell transplantation for curing children with severe autoimmune diseases: is this a valid option?Emerging concepts in haematopoietic cell transplantation.An update on stem cell transplantation in autoimmune rheumatologic disorders.Update on stem cell transplantation for systemic sclerosis: recent trial results.Is there a cure for systemic lupus erythematosus?Stem cell therapies for systemic sclerosis.Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis.Biotherapy in Inflammatory Diseases of the CNS: Current Knowledge and Applications.Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.[Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus].Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis Autologous hematopoietic stem cell transplantation as a treatment option for aggressive multiple sclerosis.Acquired haemophilia A in a patient with systemic sclerosis treated with autologous haematopoietic stem cell transplantation.Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis.Cell-based therapeutic strategies for multiple sclerosis.Late post-transplant anti-aquaporin-4 Ab-positive optic neuritis in a patient with AML.Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease.Autologous stem cell transplantation with thiotepa-based conditioning in patients with systemic sclerosis and cardiac manifestations.Evans syndrome after autologous peripheral blood stem cell transplantation for recurrent Hodgkin lymphoma.Autologous hematopoietic cell transplantation for systemic sclerosis - a challenge for the Canadian health care system.[Allogeneic stem cell transplantation : An option for autoimmune diseases?]Adrenal crisis in a 14-year-old boy 12 years after hematopoietic stem cell transplantation.

P2860

Q26471152-4EDEA051-5C19-4E78-A5F7-C34E31090FD5 Q26778199-3D366ACE-3511-48B4-9BBD-1C1C93D579CD Q26827226-98DD106F-EC37-4D7A-9CCC-311B1C588D7B Q28071992-5ACDA9D3-2EBC-4C32-B387-06CCE186A303 Q30582614-9EC93ACC-AC64-4433-ADCC-3F8ED3597325 Q30680927-C6E852AE-AA30-4728-B47D-9C56A4D6331F Q31075436-D808353F-1500-4AD6-8810-D619F5EDAB68 Q33424451-C05E0418-B23E-4DEE-B712-D78E8AFE1FB7 Q33688722-5CF3378E-0311-49C1-8FD2-5366090019B9 Q34039955-EC68CE41-141D-4F53-9BF6-8A874A32B28F Q34314312-8CF04A46-31A6-473F-BBE8-9999BD2500E5 Q34551863-9E826730-39CB-4526-8DC1-4DB749568C94 Q36020897-DBF88ACF-021B-471D-BAB2-DDFBDDD3D83E Q36735696-80713E09-55B1-43B7-AD55-CD7F428F9B00 Q37473909-39C716CA-5404-4EE5-99F9-22D411491671 Q37603718-F1CD798C-AF99-47A3-B512-8FAFF9768749 Q37995011-68E4FE4C-9BE5-449A-82C8-49BE0D8917E4 Q38004048-53C3E3CF-D04E-45E6-9696-B8FFD37F557B Q38013047-0B4B2AB0-3EBA-469E-854D-A11CC43A1FFE Q38041499-0D18BE23-65B6-4290-8C0B-2BB5332FB8C5 Q38091659-80002179-039B-4FFA-AE25-2E7C79312382 Q38095888-3E75971D-69EB-4C8F-A776-6DDBFA6A6AD1 Q38265814-4FE09A79-F35E-4B6C-8C8F-02084D46271E Q38466458-E0A270EB-CDED-40A0-BA1D-80B9D54ABF39 Q38729214-08E6942D-8EED-483D-B0E5-08ED5E816294 Q38939585-C13ADF48-E50A-4419-AED8-30F26D7FA88D Q39378263-B350EABE-85EF-4A96-B71A-BB9A86B8288F Q40545323-E3083901-E410-4D61-BC25-88595EB7EC3D Q42145052-C9C2C511-51E8-4035-9D85-8F54E593DCB8 Q44621693-6E81A08C-A4E9-45DE-BB8B-EB2CC57B4E87 Q45871388-71B8D858-FEC8-44B0-8C3C-73D8758B4DC4 Q47562795-5B94422C-FB7C-4780-BCDB-C969898C21F5 Q47885870-AE8B6F43-BF32-481A-969D-C646EA990469 Q48207843-5BED5C13-734F-4072-A430-2DDC24854541 Q48401354-9647E473-B5E4-4DDC-AD67-9DA22FF097E9 Q51166044-6E1093D0-8858-4B28-AAD6-0807A469FB1C Q53037780-4AEFC1B7-476A-4C9F-92EA-4944954E91F8 Q53724025-A384DED8-70B9-4E3B-923E-583F8E3CEFAD Q53923462-B2E20CBE-6009-415E-9C7E-B427DB372B01 Q55043234-DA989407-0C83-456A-9496-3EC2EF343936

P2860

Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party.

http://www.wikidata.org/entity/Q33395411

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@ast

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en-gb

type

label

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@ast

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en-gb

prefLabel

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@ast

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en-gb

P1433

Q33395411-C1D2D438-E300-4E53-A752-EDCAEE41C056

P1476

Q33395411-BE364532-CE2E-45EC-9AA6-CE6FA7990622

P2093

Q33395411-0EB6BCE1-204A-4705-B861-16C8C844B280

Q33395411-1154EF4A-A524-407F-A3E5-E523E2E0227C

Q33395411-18340B6C-573F-49B0-B53B-C4FFC25CD362

Q33395411-26AEC4D9-AF55-4437-99DC-D99C56DE7C60

Q33395411-3CBD7BF9-A6B9-411C-A7E0-04BF16033209

Q33395411-4AF007EF-EFCC-4AAB-BB89-0D69400C4D93

Q33395411-5B050CB4-EFA2-439A-856E-0AF77A414D0D

Q33395411-63678C6C-FC18-4738-A103-EEF092985C45

Q33395411-6C895755-C216-49E4-AD00-0EA4E07EAA63

Q33395411-6E5CB132-F95B-4602-B24E-46D475C9935D

P304

Q33395411-2AB87888-0AA7-4DF2-B151-C6BFF9D78668

P31

Q33395411-CF901882-F99B-4D4F-9875-180B395E9D11

P356

Q33395411-07FADAED-46DC-4200-9123-B819172447C7

P407

Q33395411-3F638A48-15CC-4043-87C0-92763E0AE809

P433

Q33395411-FD087CD2-E4EE-4512-8DAA-C37DE331EE60

P478

Q33395411-4042F4D8-A7C4-4642-B85E-272D3C0A326C

P50

Q33395411-28058D08-C6E7-4560-873F-218895F187D0

Q33395411-3A865722-E70B-4E37-B34F-D358F4BEE52B

Q33395411-46DA446A-5DE0-4E08-9464-CDC1A9C41733

Q33395411-7D06BF88-CB79-427A-AC35-EE0D3D02DDEE

P577

Q33395411-7DA8F6A1-ACED-430F-BC0C-E4DCE80DF4D6

P5875

Q33395411-589BFB20-E220-4A2A-8BA0-094EDF2F1972

P698

Q33395411-23DBF827-B463-44A7-8434-52E2D6DCA69E

P356

BLOOD-2011-02-336156

P1433

P1476

Secondary autoimmune diseases ...... oimmune Disease Working Party.

@en

P2093

Alan Tyndall

http://www.w3.org/2001/XMLSchema#string

Annemie Schuerwegh

http://www.w3.org/2001/XMLSchema#string

Antonia Sampol

http://www.w3.org/2001/XMLSchema#string

Athanasios Fassas

http://www.w3.org/2001/XMLSchema#string

Benedicte Dubois

http://www.w3.org/2001/XMLSchema#string

Bernd Gruhn

http://www.w3.org/2001/XMLSchema#string

Carl Philipp Schwarze

http://www.w3.org/2001/XMLSchema#string

Chiara Messina

http://www.w3.org/2001/XMLSchema#string

David Pohlreich

http://www.w3.org/2001/XMLSchema#string

Dominique Farge

http://www.w3.org/2001/XMLSchema#string

P304

1693-1698

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2011-02-336156

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Éliane Gluckman

P577

2011-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51150696

http://www.w3.org/2001/XMLSchema#string

P698

21596847

http://www.w3.org/2001/XMLSchema#string